¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Drug Resistance, Multiple, Bacterial"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 3
¿µ¹® antianginal drug ÇÑ±Û Ç×Çù½ÉÁõÁ¦
¼³¸í   
  Çù½ÉÁõÀº ½ÉÀ嵿¸ÆÀÇ Ç÷·ù¸¦ ÁÁ°ÔÇϰųª ½ÉÀåÀÌ Ç÷·ù¿¡ ºñÇØ¼­ ¸¹Àº ÀÏÀ» Çϴ °ÍÀ» ¾ïÁ¦ÇÔÀ¸·Î½á Ä¡·áµÉ ¼ö ÀÖ´Ù. ¨ç nitrate°èÅëÀÇ ¾à¹°: Ç÷°üÀ» À̿ϽÃ۴ ÀÛ¿ëÀ» ÇÔÀ¸·Î½á ½ÉÀ嵿¸ÆÀÇ Ç÷·ù¸¦ ÁÁ°Ô ÇÑ´Ù. ¨è Ä®½·Åë·ÎÂ÷´ÜÁ¦(verapamil, nifedipine): ¸ðµç ±ÙÀ°ÀÇ ¼öÃà¿¡´Â CaÀÌ °ü¿©ÇÑ´Ù. Áï CaÀÌ ÀÖ¾î¾ß¸¸ ±ÙÀ°ÀÇ ¼öÃàÀÌ °¡´ÉÇØÁø´Ù. ±×·¯¹Ç·Î CaÀÌ ¼¼Æ÷¼ÓÀ¸·Î µé¾î°¡´Â °ÍÀ» ¾ïÁ¦Çϴ ¾àÁ¦´Â ±ÙÀ°ÀÇ ¼öÃàÀ» ¸·´Â´Ù. ÀÌ ¾àÀº ½ÉÀåÀÇ ±ÙÀ°¿¡ ÀÛ¿ëÇÏ¿© ½ÉÀå ±ÙÀ°ÀÇ ¼öÃàÀ» ¾ïÁ¦Çϸ砽ÉÀåÀÌ °úµµÇϰԠÀÏÇϴ °ÍÀ» ¸·°í, ¶Ç ½ÉÀ嵿¸ÆÀÇ ¼öÃà¿¡ °ü¿©Çϴ ±ÙÀ°¿¡ ÀÛ¿ëÀ» ÇÏ¿© ½ÉÀ嵿¸ÆÀ» À̿ϽÃÄѼ­ Ç÷·ù¸¦ ÁÁ°Ô ÇÑ´Ù.
  
  ¨é º£Å¸Â÷´ÜÁ¦(beta-blocker): ½ÅüÀÇ ¿îµ¿·®À̳ª ±âŸÀÇ ¿ä±¸¿¡ ÀÇÇØ¼­ ½ÉÀåÀ» »¡¸® ¶Ù°ÔÇϴ ½Å°æÀº ¹Ù·Î º£Å¸-±³°¨½Å°æÀÌ´Ù. ±³°¨½Å°æ°è¶õ »ç¶÷ÀÌ À§±ÞÇÑ »óȲ¿¡¼­ ÀÛ¿ëÇϴ ÀÚÀ²½Å°æ°èÀÌ´Ù. Áï »ç¶÷ÀÌ ±äÀåÇϰųª ½Î¿ï °æ¿ì¿¡ ÀüÇüÀûÀ¸·Î ±³°¨½Å°æ°è°¡ ÀÛ¿ëÇÑ´Ù. Áï ½ÉÀåÀÌ ¶Ù°Å³ª ¼ÒÈ­°¡ ¾ÊµÇ°Å³ª µ¿°øÀÌ Ä¿Áö´Â °Í µûÀ§°¡ ¹Ù·Î ±³°¨½Å°æ°èÀÇ ¿ªÇÒÀ̶ó°í ÇÒ ¼ö ÀÖ´Ù. ÀÌ ±³°¨½Å°æ°è¿¡¼­ ¸»ÃÊÀå±â¿¡ º¸³»´Â ½Å°æÀÌ ±³°¨½Å°æÀÌ´Ù. ±×·¯¹Ç·Î ½ÉÀå¿¡¼­ ½ÉÀåÀ» ½Åü¿¡ Çʿ信 µû¶ó¼­ ¸¹Àº ÀÏÀ» ÇϰÔÇϴ ½Å°æÀ» Â÷´ÜÇÒ °æ¿ì¿¡´Â Çù½ÉÁõÀ» Ä¡·áÇÒ ¼ö ÀÖ°Ô µÈ´Ù(½ÉÀåÀÇ »ê¼Ò³ª ±âŸ ¿µ¾çºÐÀÇ ¼ö¿ä¸¦ ÁÙÀδÙ).
  
  
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • hereditary multiple exostosis
    À¯Àü´Ù¹ß»Àµ¹ÃâÁõ, À¯Àü´Ù¹ß¿Ü°ñÁõ
  • heterogeneous resistance
    ºñ±ÕÀÏÀúÇ×
  • insulation resistance
    Àý¿¬ÀúÇ×
  • insulin resistance
    Àν¶¸°ÀúÇ×, Àν¶¸°³»¼º
  • internal resistance
    ³»ºÎÀúÇ×
  • multidrug resistance
    ´Ù¾àÁ¦³»¼º
  • multiple
    ´Ù¹ß-, ¿©·¯-, ¹µ-, ´Ù¼ö-, ´ÙÁß-, ´Ù-
  • multiple abscess
    ¹µ°í¸§Áý, ´Ù¹ß³ó¾ç
  • multiple allele
    ¹µ¸Â¼¶À¯ÀüÀÚ, º¹¼ö´ë¸³À¯ÀüÀÚ
  • multiple birth
    ´Ùžƺи¸
  • multiple bond
    ´ÙÁß°áÇÕ
  • multiple character
    ´ÙÁß¼º°Ý
  • multiple correlation
    ´ÙÁß»ó°ü
  • multiple division
    º¹Çպп­
  • multiple embolism
    ´Ù¹ß»öÀüÁõ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • antiviral drug
    ¹ÙÀÌ·¯½º¾à, Ç×¹ÙÀÌ·¯½ºÁ¦
  • nonsteroidal antiinflammatory drug
    ºñ½ºÅ×·ÎÀ̵å¼Ò¿°Á¦, ºñ½ºÅ×·ÎÀ̵åÇ׿°ÁõÁ¦
  • psychoactive drug
    Á¤½ÅÀÛ¿ë¾à
  • tranquilizing drug
    Á¤½Å¾ÈÁ¤Á¦, Á¤¿ÂÁ¦
  • tuberculostatic drug
    Ç×°áÇÙÁ¦
  • therapeutic drug monitoring
    Ä¡·á¾à¹°³óµµ°¨½Ã
  • adverse drug reaction
    ¾à¹°ºÎÀÛ¿ë
  • drug treatment
    ¾à¹°Ä¡·á
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • hereditary multiple exostosis
    À¯Àü´Ù¹ß»Àµ¹ÃâÁõ
  • multiple embolism
    ´Ù¹ß»öÀüÁõ
  • multiple epitheliomatosis
    ´Ù¹ß»óÇÇÁ¾Áõ
  • multiple excitation
    ¹Ýº¹ÈïºÐ
  • multiple fetation
    ´Ù¼öÀÓ½Å
  • multiple fission
    ¹µºÐ¿­, ´Ù¼öºÐ¿­
  • multiple fracture
    ´Ù¹ß°ñÀý
  • multiple sclerotic gait
    ´Ù¹ß°æÈ­Áõ°ÉÀ½
  • multiple infection
    ¿©·¯¹ø°¨¿°
  • multiple intussusception
    ´Ù¹ßâÀÚ°ãħÁõ
  • multiple field irradiation
    ´ÙÁ¶»ç¿µ¿ªÁ¶»ç
  • multiple keratoacanthoma
    ´Ù¹ß°¢Áú°¡½Ã¼¼Æ÷Á¾
  • multiple labor
    ´Ù»ê, ´Ùźи¸
  • multiple
    ´Ù¹ß-, ¿©·¯-, ¹µ-, ´Ù-
  • multiple myeloma
    ´Ù¹ß°ñ¼öÁ¾
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • heat resistance
    ³»¿­¼º(ËÀËçËÛ).
  • immunological resistance
    ¸é¿ªÀúÇ×.
  • index of resistance
    ÀúÇ×Áö¼ö(î½ù÷ò¦â¦).
  • insulin resistance
    Àν¶¸°ÀúÇ×¼º.
  • phage resistance
    ÆÄÁö³»¼º
  • plasmid, resistance (R)
    ³»¼ºÇö󽺹̵å, RÇö󽺹̵å
  • platinum resistance furnace
    ¹é±Ý·Î (ÛÜÐÝÖÓ).
  • pleiotropic resistance
    ´Ù¸é¹ßÇö¼º³»¼º
  • progressive resistance
    Á¡ÁõÀúÇ×(ïÂñòî½ù÷).
  • progressive resistance exercise
    Á¡ÁõÀúÇ׿(ïÂñòî½ù÷ê¡ÔÑ).
  • pulmonary flow resistance
    Æó±â·ùÀúÇ×(øËѨêüî½ù÷).
  • pulmonary vascular resistance
    ÆóÇ÷°üÀúÇ×(øËúìηî½ù÷), Æó¼øÈ¯ÀúÇ×.
  • radiation resistance
    ¹æ»ç¼±ÀúÇ×¼º
  • ADR : adverse drug reaction
    ¾à¹°À¯ÇØÀÛ¿ë(å·ÚªêóúªíÂéÄ).
  • IND : investigational new drug
    ½ÃÇè¿ë½Å¾à.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • bacterial contamination
    ¼¼±Õ(¼º)¿À¿°(çýæø)
  • bacterial culture
    ¼¼±Õ¹è¾ç(¡­ÛÆå×).
  • bacterial culture
    ¼¼±Õ¹è¾ç(ÛÆå×)
  • bacterial culture system
    ¼¼±Õ¹è¾ç±â, ¼¼±Õ¹è¾çÀåÄ¡
  • bacterial cytology
    ¼¼±Õ¼¼Æ÷ÇÐ(¡­á¬øàùÊ).
  • bacterial decomposition
    ¼¼±Õ¼º ºÐÇØ (¡­ÝÂú°).
  • bacterial density
    ¼¼±Õ¹Ðµµ(¡­ÚËöô).
  • bacterial disease
    ¼¼±ÕÁúȯ
  • bacterial disease
    ¼¼±Õ¼º Áúȯ(¡­òðü´)
  • bacterial disease
    ¼¼±Õ¼º Áúȯ(¡­òðü´).
  • bacterial endocarditis
    ¼¼±Õ¼º ½É³»¸·¿° (¡­ãýҮدæú).
  • bacterial endocarditis
    ¼¼±Õ¼º ½É³»¸·¿°(á¬Ð¶àõãýҮدæú)
  • bacterial endotoxin
    ¼¼±Õ³»µ¶¼Ò.
  • bacterial exotoxin
    ¼¼±Õ¿Üµ¶¼Ò.
  • bacterial extract
    ¼¼±Õ(¼º)ÃßÃâ¹°(¡­õÎõóÚª).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
PVR peripheral vascular resistance; perspective volume rendering; poliovirus receptor; postvoiding resid...
RVR reduced vascular response; renal vascular resistance; repetitive ventricular response; resistance to...
TPR temperature, pulse, and respiration; testosterone production rate; third party reimbursement; total ...
TPVR total peripheral vascular resistance; total pulmonary vascular resistance
MDR Multi-Drug Resistance
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
BT Bacterial Translocation
BE Bacterial endocarditis
BKD Bacterial kidney disease
CBP Chronic bacterial prostatitis
NBTE Non-bacterial thrombotic endocarditis
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • activated protein C resistance
    Ȱ¼ºÈ­ C ´Ü¹é ³»¼º
  • airway resistance
    ±âµµ ÀúÇ×
  • androgen resistance syndrome
    ³²¼º È£¸£¸ó ³»¼º ÁõÈıº, ³²¼º È£¸£¸ó ÀúÇ× ÁõÈıº
  • capillary resistance test
    ¸ð¼¼Ç÷°ü ÀúÇ×¼º ½ÃÇè
  • corrosion resistance
    ³»½Ä¼º, ºÎ½Ä ³»¼º
  • flow resistance
    È帧 ÀúÇ×, À¯·® ÀúÇ×
  • hepatic vascular resistance
    °£ Ç÷°ü ÀúÇ×
  • immunological resistance
    ¸é¿ª ÀúÇ×
  • magnetic resistance
    ÀÚ±â ÀúÇ×
  • peripheral resistance unit
    ¸»ÃÊ ÀúÇ× ´ÜÀ§
  • platinum resistance furnace
    Àü±â ¼Ò¼º·Î, ¹é±Ý ·Î
  • progressive resistance
    Á¡Áõ ÀúÇ×
  • radiation resistance
    ¹æ»ç¼± ÀúÇ×
  • resistance
    °ÅºÎ, ÀúÇ×, ÀúÇ×¼º, ³»¼º
    Àü·ù Åë°ú¿¡ ´ëÇÏ¿© µµÃ¼¿¡ ÀÇÇÑ ÀúÇ×. Á¤½Å ºÐ¼®¿¡ À־´Â ¾ï¾ÐµÈ °ÍÀÌ ÀǽÄÀ¸·Î µÇ´Â °Í¿¡ ´ëÇÑ ÀúÇ×. Á¤»óÀÇ »ý¹°ÀÌ È¯°æ³»ÀÇ µ¶¹°, ¿¹ÄÁµ¥ µ¶, µ¶¼Ò, Àڱع°, º´¿ø¼º ¹Ì»ý¹° µî¿¡ ´ëÇÏ¿© ÀÚ¿¬ÀûÀ¸·Î °®´Â ³»¼º.
  • resistance factor
    ³»¼º ÀÎÀÚ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
penicillin resistance <microbiology, pharmacology> Nonsusceptibility of an organism to the action of penicillins.
(12 Dec 1998)
peripheral resistance The total resistance to flow of blood in the systemic circuit; the quotient produced by dividing the mean arterial pressure by the cardiac minute-volume.
Synonym: peripheral resistance.
(05 Mar 2000)
chloramphenicol resistance <microbiology, pharmacology> Nonsusceptibility of a bacterium to the action of chloramphenicol, a potent inhibitor of protein synthesis in the 50s ribosomal subunit where amino acids are added to nascent bacterial polypeptides.
(12 Dec 1998)
methicillin resistance Non-susceptibility of a microbe to the action of methicillin, a semi-synthetic penicillin derivative.
(12 Dec 1998)
multidrug resistance The insensitivity of various tumours to a variety of chemically related anticancer drugs; mediated by a process of inactivating the drug or removing it from the target tumour cells.
(05 Mar 2000)
mutual resistance An interaction between chemicals in which one partially or completelyinhibits the effect of the other (for example, a drug that blocks a hormone's receptor site would be a hormone antagonist).
(09 Oct 1997)
cross-resistance <immunology, microbiology> Immunologic resistance to the pathogenic effects of a microorganism because of previous exposure to another species or type having cross reactive antigens.
This phenomenon is seen in microbes that acquire resistance to one drug through direct exposure and turn out to have resistance to one or more other drugs to which it has not been exposed. Cross-resistance arises because the mechanism of resistance to several drugs is the same and arises through the identical genetic mutations.
(09 Oct 1997)
sisomicin-gentamicin resistance ribosomal RNA methylase <enzyme> Catalyses the methylation of 30s ribosomal units to confer sisomicin-gentamicin resistance in micromonospora zionensis
Registry number: EC 2.1.1.-
Synonym: sgm gene product, sgm methylase
(26 Jun 1999)
synaptic resistance The ease or difficulty with which a nerve impulse can cross a synapse.
(05 Mar 2000)
systemic vascular resistance An index of arteriolar compliance or constriction throughout the body; equal to the blood pressure divided by the cardiac output.
(05 Mar 2000)
dicumarol resistance A well-defined autosomal dominant resistance to it, over and above general variability in tolerance to the drug.
(05 Mar 2000)
impact resistance The ability of a lens for eyewear to withstand impact without shattering or breaking, i.e., of a 3/8 -inch steel ball dropped 50 feet; criteria for determination of impact resistance are specified by U.S. Regulations.
(05 Mar 2000)
inductive resistance The weakening of an alternating electric current by passage through a coil of wire or a condenser.
Synonym: inductive resistance.
(05 Mar 2000)
insecticide resistance The development by insects of resistance to insecticide.
(12 Dec 1998)
insulin resistance Many people with noninsulin-dependent diabetes produce enough insulin, but their bodies do not respond to the action of insulin. This may happen because the person is overweight and has too many fat cells, which do not respond well to insulin. Also, as people age, their body cells lose some of the ability to respond to insulin. Insulin resistance is also linked to high blood pressure and high levels of fat in the blood. Another kind of insulin resistance may happen in some people who take insulin injections. They may have to take very high doses of insulin every day (200 units or more) to bring their blood glucose (sugar) down to the normal range.
(09 Oct 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • hard drug
    ½À°ü¼º ¸¶¾à
  • miracle drug
    Ưȿ¾à;¿µ¾à
  • misbranded drug
    ºÎÁ¤ Ç¥½Ã ÀǾàǰ
  • mood drug
    ±âºÐ ¾à(ÈïºÐÁ¦,ÁøÁ¤Á¦ µî)
  • prescription drug
    ÀÇ»çÀÇ Ã³¹æÀüÀÌ ÇÊ¿äÇÑ ¾à
  • soft drug
    ¾àÇÑ ¸¶¾à(¸¶¸®È­³ª µûÀ§)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á